Effect and Potential Mechanism of Electroacupuncture Add-On Treatment in Patients with Parkinson’s Disease

Table 1

Demographic features and baseline characteristics of patient in the D + EA and D groups.

	D + EA group	D group
Gender, male/total ()	13/28	9/20	0.922^c
Age (years, mean ± SD)	62.1 ± 8.7	59.1 ± 12.4	0.334^a
Duration (years, mean ± SD)	2.9 ± 2.9	2.7 ± 2.3	0.719^a
Tremor type ()	3	4	0.628^c
Rigidity-bradykinesia type ()	8	5	0.784^c
Mixed type ()	17	11	0.692^c
H-Y Stage (stage, mean ± SD)	2.0 ± 0.7	2.0 ± 0.8	0.907^a
LED (mg, mean ± SD)	104.1 ± 253.2	160.6 ± 260.0	0.376^a
UPSRS III (points, mean ± SD)	25.6 ± 2.8	23.3 ± 13.0	0.583^a
PSQI [points, median (quartile)]	21.0 (18.0~25.3)	16.5 (13.8~23.0)	0.088^b
HAMD [points, median (quartile)]	12.0 (7.0~19.0)	7.5 (5.0~17.8)	0.098^b
HAMA [points, median (quartile)]	13.5 (10.0~16.0)	9.0 (6.3~14.0)	0.139^b
MMSE [points, median (quartile)]	29.0 (28.0~30.0)	28.0 (25.0~29.0)	0.065^b
MoCA [points, median (quartile)]	25.0 (22.0~28.0)	23.5 (17.3~27.0)	0.252^b

Values are means ± standard for Student’s -test.
^bValues are median (lower quartile, upper quartile) for the Kruskal-Wallis test.
^cValues are discrete variables for the test.
LED: levodopa equivalent dose.